Skip to main content
Fig. 1 | BMC Cancer

Fig. 1

From: Impact of pretreatment anemia on upfront abiraterone acetate therapy for metastatic hormone-sensitive prostate cancer: a multicenter retrospective study

Fig. 1

Patient evaluation. Patients with high tumor burden (CHAARTED high-volume and/or LATITUDE high-risk) were evaluated in this study. We identified 67 and 135 patients in the ADT/CAB and upfront groups, respectively. We divided the patients according to the presence of pretreatment anemia into the non-anemia-ABI, anemia-ABI, non-anemia-ADT/CAB, and anemia-ADT/CAB groups

Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us